Session (CTI)

Healthcare evidence is being evaluated under increasing pressure as decision expectations continue to diverge across major global markets, and pricing reforms such as international reference pricing (IRP) mechanisms and other pricing reforms, such as Most-Favored Nation (MFN), are increasing the downstream policy and market implications of access decisions across regions. Global evidence programs increasingly need to satisfy different evidentiary standards and decision preferences across regulators, HTA bodies, and payers in the United States, Europe, and Asia-Pacific.
Comparative evidence, real-world data, modelling assumptions, uncertainty, and affordability are not weighed consistently; meaning evidence that is sufficient in one decision context may still leave important gaps in another. This session will examine how globally coordinated evidence strategies can more effectively anticipate where regional divergence becomes decision-critical.
Drawing on recent policy and HTA developments, including policy pricing developments in the United States, Europe’s JCA, and evolving reimbursement expectations across Asia-Pacific markets, the discussion will focus on where divergence matters most, including comparator selection, endpoint hierarchy, indirect treatment comparisons, uncertainty management, and approaches to communicating evidence for decision-making.
The session will also discuss how global evidence plans must increasingly account for interdependencies between pricing, reimbursement, and evidence requirements across markets when planning global evidence generation strategies.
Sponsored by Corporate Partner, Parexel